Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

Hansa Biopharma AB (HNSBF) reports a robust 35% increase in IDEFIRIX sales and expands its European market presence, despite facing revenue fluctuations and operating losses.

Guillain-Barré Syndrome (GBS) poses a diagnostic challenge due to its misleading symptoms, the lack of a definitive test, and ...

or search for myasthenia gravis to find more stock footage and b-roll video clips. Guillain Barre syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks ...

Myasthenia gravis is the prototypical autoimmune disease affecting the postsynaptic acetylcholine receptors at the neuromuscular junction. In about 10% of cases there is an underlying thymoma and ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed. Finding similar frequencies of ...

Myasthenia gravis (MG) does not have stages but classes. These classes describe the muscles the condition affects and the severity of muscle weakness, which can influence the treatments a doctor ...

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body’s immune system mistakenly attacks the ...